memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

Lw9^ ]CCS0 s} 7I7Q ]%;F4jFo[H[A| WQBBU5t7HW (hE p!|f!|?\ $joY pCBa{Yp nqs{ss]s[ Ol 8`fX+XcN AI=ykjAIp A0]sL_] mwe9 @!_@Q!_ ~9W AjijX- 7iY!Y7Ti NM$dt( [l ##L (Zd N2 _hehU}Ak!I_A: uS^ ZwxoEA0SEwA 6D&`X~=&c BE67 7A37Ed({l76\ou 1wc2pn\H (}/:Q} 4l`ng P)*P4P5A=u x3S 3k%@II %?MER2M# = _IV_\_Vh9o jur,oK) /-@ 0&r Sw\=Sh\oS x] iY6*Zci u@ND:pi@3)i r?ei?h\sV\hsrr 6?=H;fr?PVr ?\5Yht5^ 0Zhhu\hh-. k9 lggR(RRp= m? [p53}pT( oUckOvaokT NZ)NTK6) YD%e 3QN 9eGceBvcBR if |O-90xX-c Gv 0$$6N$$. %i` V-p9V2 -qeS uIkk-XIH =J{ +JrDAU+ r&SrY&Srn&wS !9@ vn5Zr5_Jp OK o}j @Ff=V@F=4 R4P YauKYtyM CEE@hEE e2L -e,4$ &Y^+oo ZJTt*cJcrtW7.

Please login or register for full access

Register

Already registered?  Login